Verastem's quest to develop drugs that block cell signaling pathways that cancer stem cells need to survive hits a major milestone in mid-2013, when it launches a 350-patient clinical trial of a potential companion biomarker test for its investigative mesothelioma drug treatment.
Last year AstraZeneca's MedImmune did about 20 biologics deals, not counting the academic pacts it assembled. Bahija Jallal, head of R&D, tells FierceBiotech there will be no letup in talent scouting: "If we do as little or more than last year, I would be happy."
Rival drug combination works to perfection for toughest hep C patient group, and some patients and doctors appear willing to consider taking matters into their own hands.
The federal government has put the brakes on the largest and most advanced study of a vaccine against HIV infection after an independent data and safety monitoring board found that the vaccine regimen did not benefit patients.
Doctors at the University of Mississippi Medical Center accurately gauged whether antiangiogenic treatments are working in melanoma patients by using CT imaging combined with measurements of a key biomarker.
India's government is struggling to crack down on loosely regulated clinical trials that have killed hundreds of patients around the country, and while it's unclear if its efforts have made the process safer, they've certainly slowed things down.
With new regulations in place following a hullaballoo over the number of deaths recorded in drug studies, it appears as if the once-thriving clinical trial business is barely registering a heart beat.
Alkermes spinout Civitas Therapeutics today reported positive topline results from a Phase II clinical trial of its Parkinson's drug CVT-301, which uses a respiratory delivery system to provide quick relief to patients experiencing motor fluctuations common to long-term treatment of the disease.
Covance is counting on Asia for an explosion in drug development, and the company has expanded its core lab capacity by 50% in Singapore to serve the growing market for clinical testing in the region.
Eli Lilly has added to a body of positive Phase III data for its once-weekly GLP-1 candidate dulaglutide, with two more late-stage studies that have met their main goals. And the data come as the company counts on drugs from its diabetes pipeline to improve its fortunes after suffering from generics competition to fading moneymakers such as Zyprexa.